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studies complement research of David Lewis and his team at
the Institute of Naval Medicine, where they had previously
characterized the inﬂuence of some important stressors on
immune function and disease susceptibility in Royal Marine
training.11
The effect of energy deﬁcit on compromised immune func-
tion may reﬂect diversion of restricted energy availability to
higher priority survival functions. High intensity training (i.e.,
elevated metabolic demands) by itself does not seem to be
the problem, as demonstrated in this most recent study with
asymptomatic, ﬁt, and energy-balancedRoyalMarines. Disease
resistance does seem to be compromised with some level of
energy deﬁcit. New data describe a rich environment of
metabolic signals inmilitary trainingwith high energy demands
that were not met by energy intake (Norwegian ski patrol).12
These signals might be important to moderating microbiome
composition and behavior and this is what bears further
investigation. A pathogenic connection may come clearer
from studies of skin and oropharyngeal microbiome responses
to host energetics. Most speciﬁcally, the interaction between
host status and colonizing species and quorum sensing signals
should be considered in military ﬁeld studies such as those
that have characterized the variety of species involved in
speciﬁc pathogenic outcomes.1,3
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Prevalence of HLA-B*5701 in a Kenyan
population with HIV infection
Dear Editor,
We read with interest the article published in your
Journal entitled “Real-world persistence with antiretroviral
therapy for HIV in the United Kingdom: a multicentre retro-
spective cohort study”1 which concluded that treatment
discontinuation attributable to toxicity proﬁle is not an
uncommon event. They also acknowledged lack of data
collection on HLA-B*5701 status, which would heavily inﬂu-
ence initial ART regimen and the choice to discontinue
medication.
Of the 25.6 million living with Human Immunodeﬁciency
Virus (HIV) in Africa, an estimated 1.6 million people live in
Kenya.2 With an HIV prevalence of 5.6%, Kenya has upscaled
HIV treatment and care in the past 10 years to cover 80% of
those requiring therapy.2 The current Kenyan guidelines, as
in the case of many developing countries, rely on WHO
guidelines.3,4 Abacavir is a nucleoside reverse transcriptase
inhibitor (NRTI) used for treating HIV infection and is recom-
mended as both ﬁrst and second line drug options. A barrier
to prescribing of abacavir in Kenya is the fear of Abacavir
Hypersensitivity Reaction, and this has been compounded by
the lack of availability of testing for HLA-B*5701 testing. The
Kenyan population is heterogeneous, consisting of 42 tribes
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with themain ethnic groups being Bantu, Nilotes and Cushites.
In our study, we have determined the prevalence of HLA-
B*5701 in the black HIV positive population in Kenya using a
cross sectional epidemiological survey. We recruited 1004
patients from three HIV centers: the Aga Khan University
Hospital Nairobi, Mbagathi Hospital and Machakos Hospital
in Kenya after ethics approval was sought from the Research
Ethics Committee in Aga Khan University and from the ethics
boards of Mbagathi and Machakos hospitals.
We included HIV positive individuals who reported both
parents as being from the 42 tribes in Kenya, regardless of
previous exposure to abacavir. After obtaining written in-
formed consent, 5 ml of venous blood was drawn into EDTA
tubes.
DNA extraction was performed using the protocol pro-
vided in the PureLink TM kit which was provided by Invitrogen
Lab5 and followed by quantiﬁcation using the Nano drop
1000 spectrophotometer (Nano Drop Technologies, DE, USA).
DNA samples were then stored at −20 °C awaiting HLA-
B*5701 screening, which was performed using the Real TM®
PCR test provided and produced by Sacace.6 This was con-
ducted according to the manufacturer’s protocol and then
run on the Qiagen Rotor Gene thermal cycler. External val-
idation was performed using positive and negative samples
from our lab which were sent to Imperial College, London,
UK.
Analysis was conducted using SPSS and Wilson score used
to determine the conﬁdence interval.
Results
Out of a total of 1004 samples, 1002 were included in the
analysis, and eight samples tested positive for the HLA-
B*5701 gene amounting to a prevalence of 0.8% (CI 0.41–
1.57) (Fig. 1, Table 1).
Our study revealed that the prevalence of HLA B*5701
gene in this HIV-infected Kenyan population was 0.8%. There
is no statistical signiﬁcance difference in the prevalence
between ethnic groups.
Previous studies conducted in African Americans have
revealed a lower prevalence of the gene as compared to
Caucasians, at 2–3%.7 Other studies done in Black Africans of
Bantu origin revealed a prevalence of 0.52%(8). Further-
more, other genetic mapping studies have been performed
among the Luo and the Nandi community (which is a sub-
tribe within the greater Kalenjin community), with a prev-
alence of 0.8% which is consistent with our study.8,9
Our study’s prevalence of 0.8% is much lower than that
reported in the African American population and is similar to
that reported in the Bantu population. This may be an expla-
nation as to why AHR is not a major problem in the Kenyan
setting.
Ideally HLA-B*5701 testing should be performed prior to
abacavir use, however where it is not available and abacavir
is used the incidence of AHR is likely to be low in a black
Kenyanpopulation. Education shouldbeprovided to thepatient
and health care provider regarding the possible side effects
and the health care provider should also be vigilant for the
possibility of AHR developing.
Assessed for eligibility 
(n = 1236)  
Consent taken and 
blood samples drawn
Not meeting criteria for 
analysis: Asian origin
(n = 2)
Analysed (n = 1002)
Sample taken for DNA 
extraction, quantification 
and screening for gene
Declined to 
participate - 232
Recruited 
(n = 1004)
Figure 1 Study ﬂow diagram.
Table 1 Prevalence of HLA B*5701 within ethnic groups.
Ethnic group N HLA B*5701 Status Positive HLA B*5701 status P valuea
Positive Negative % 95% CI
Bantu 646 6 640 0.92 0.42–2 0.891
Nilotes 226 2 224 0.88 0.24–3
Cushites 6 0 6
Others 124 0 124
Overall 1002 8 994 0.8 0.41–1.57
a P value of difference between the different ethnic groups.
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Cost effectiveness of screening for dengue
infection in a UK teaching hospital
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Dear Editor,
We note with interest the recent Letter from our Singa-
porean colleagues describing dengue and Zika virus
co-infections.1 In theUK, such infections aremostly imported,2
and our local testing involves sending samples to a national
reference laboratory, where the possibility of co-infections
are covered by a panel of tests covering various viruses
where infection presents with similar clinical features, such
as dengue, chikungunya and Zika virus.
We analysed the admission clinical and laboratory param-
eters that were most closely associated with a positive diag-
nosis of acute dengue infection, in returning travellers in a
UK teaching hospital over a 3-year period (2014–2016 inclu-
sively), including the data from 173 patients (i.e. 2014: 43;
2015: 68; 2016: 62 patients).
The UK is not a dengue-endemic area so certain case
criteria are required to prompt a consideration of acute
dengue infection. These include: return from a country where
dengue is endemic, clinical features compatible with dengue
appearing within 3–10 days (more typically an incubation
period of 4–7 days), i.e. fever, rash, headache, malaise,
retro-orbital pain, myalgia and arthralgia.3 The more severe
haemorrhagic manifestations of dengue are not seen in this
patient cohort and the traditional tourniquet test is not
usually performed during the routine clinical examination of
these patients.
Along with a compatible travel history and clinical fea-
tures we examined the admission haematology and biochem-
ical laboratory parameters andperformed correlation statistics
to investigate which of these variables either singly or in
combination were most accurately associated with a diag-
nosis of acute dengue infection. This was deﬁned as the
detection of dengue RNA by PCR, the presence of dengue-
speciﬁc IgM or documented dengue IgG seroconversion.
In addition, we included the requesting team (general prac-
titioners – GPs, general medicine, or infectious diseases) as
an additional parameter to include in the correlation analysis.
The dengue virus testing was performed at the Rare and
Imported Pathogens Laboratory (RIPL) (Porton Down, Salis-
bury, UK). The main test options at the PHE RIPL reference
laboratory are either dengue IgG and IgM serology (if pre-
sentingmore than 5 days after symptomonset) and/or dengue
reverse-transcription polymerase chain reaction (RT-PCR, if
presenting within 5 days of symptom onset) – NS1 antigen
testing is not routinely offered. This test is a routine geo-
graphical panel (including serology and PCR as appropriate,
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